Abstract
Background: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has demonstrated a survival benefit and reduces heart failure h......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
